HC Wainwright Reaffirms Buy Rating for Affimed (NASDAQ:AFMD)

HC Wainwright reissued their buy rating on shares of Affimed (NASDAQ:AFMD) in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. Stifel Nicolaus lowered their price target on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Trading Down 3.5 %

AFMD stock opened at $2.18 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. Affimed has a twelve month low of $2.02 and a twelve month high of $8.95. The firm has a 50 day simple moving average of $3.10 and a 200-day simple moving average of $4.19.

Institutional Investors Weigh In On Affimed

A number of large investors have recently made changes to their positions in AFMD. Jane Street Group LLC purchased a new stake in shares of Affimed during the third quarter worth $44,000. Point72 Asset Management L.P. lifted its stake in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the last quarter. FMR LLC raised its holdings in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares in the last quarter. Intellectus Partners LLC boosted its holdings in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the period. Finally, Choreo LLC bought a new position in shares of Affimed in the second quarter worth about $54,000. Institutional investors and hedge funds own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.